Fig. 5.

Intracerebral injection of h19m28z CAR T cell treatment leads to reduced PCNSL growth, more tumor regressions, and a higher number of intratumoral CAR T cells compared with mock CAR T cell treatment. (A and B) Intracerebral, 2D tumor area assessed by in vivo microscopy after mock and h19m28z CAR T cell treatment. Individual (A) and pooled (B) tumor size. Results from 3 independent experiments. (C) Intracranial tumor volume measured via immunofluorescence 28 d after T cell injection in mock or h19m28z CAR T cell-treated mice without cranial window implantation (n = 7 per group from 2 independent experiments). (D) Intratumoral CAR T-cell number per 1 mm³ tumor volume 28 d after intracerebral CAR T cell injection. (A and B) n = 5 and 6 mice for mock and h19m28z CAR T cell-treated mice, respectively. (C and D) n = 7 mice per group from 2 independent experiments. A 2-way ANOVA followed by Sidak’s multiple comparisons test (B) or Mann–Whitney U test (C and D). Data are shown as mean ± SEM (B) or mean + SEM (C and D). *P < 0.05.